This strategic investment will accelerate KÄÄPÄ Biotech’s mission to bring premium, traceable, and clinically validated NordRelease functional mushroom ingredients to the forefront of global wellness and health KÄÄPÄ Biotech, a biotechnology company specialised in…

This strategic investment will accelerate KÄÄPÄ Biotech’s mission to bring premium, traceable, and clinically validated NordRelease functional mushroom ingredients to the forefront of global wellness and health

KÄÄPÄ Biotech, a biotechnology company specialised in researching, innovating, developing, producing and selling functional mushroom products, announced the successful closing of a €9,000,000 strategic investment. This major milestone underscores the company’s market-leading position and highlights the ambitious growth plans in the global nutraceutical market. 

The funding round was led by PeakBridge, a distinguished global agri-food tech fund manager and member of the Edmond de Rothschild Private Equity partnership, together with Zintinus, a Food Tech sector venture capital fund, aligned with KÄÄPÄ Biotech’s vision for driving innovation in health and wellness sectors.

This strategic investment will accelerate KÄÄPÄ Biotech’s mission to bring premium, traceable, and clinically validated NordRelease functional mushroom ingredients to the forefront of global wellness and health. The funding will enable the company to increase production capacity, expand vertical integration, scale operations, and strengthen the position of its NordRelease ingredients as a leader in the global nutraceutical market, and meet the surging demand from international customers across wellness, nutrition, and supplement sectors.

Eric Puro, CEO and Co-Founder of KÄÄPÄ Biotech, commented, “The functional mushroom market continues to expand rapidly, with the sector fueled by increasing customer demand for high-quality, trustworthy, and science-backed functional mushroom products. We are honored that more than 180 companies across over 20 markets trust us as their preferred partner.
“This strategic investment from both PeakBridge and Zintinus represents a strong vote of confidence in our vision, technology, and team. We are overjoyed by the strengthening relationship with PeakBridge, who invested in us earlier this year. In addition to the strategic partnership and funding, PeakBridge’s tailored value-add programmes for portfolio companies are a cornerstone of their partnership approach, guided by a team with deep food industry expertise. We are equally grateful for the valuable funding, strategic connections, and industry expertise that Zintinus contributes to our ongoing growth. This investment marks a major milestone as we continue scaling our operations to meet global demand while leading innovation in mushroom biotech.”